Edition:
United Kingdom

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

18.34EUR
2:24pm BST
Change (% chg)

€0.17 (+0.94%)
Prev Close
€18.17
Open
€18.17
Day's High
€18.49
Day's Low
€17.97
Volume
130,463
Avg. Vol
311,485
52-wk High
€24.96
52-wk Low
€15.54

Latest Key Developments (Source: Significant Developments)

Genfit Announces Positive 36-Month DSMB Recommendation For Continuation Of Phase 3 RESOLVE-IT Study
Tuesday, 14 May 2019 

May 14 (Reuters) - GENFIT SA ::GENFIT: POSITIVE 36-MONTH DSMB RECOMMENDATION FOR CONTINUATION OF PHASE 3 RESOLVE-IT STUDY OF ELAFIBRANOR IN NASH.POSITIVE RECOMMENDATION CONSISTENT WITH PREVIOUS GUIDANCE, SUPPORTING FAVORABLE SAFETY PROFILE OF ELAFIBRANOR.TOP-LINE INTERIM RESULTS ARE EXPECTED TO BE ANNOUNCED AT END OF 2019.IF POSITIVE, INTERIM DATA WOULD SUPPORT ACCELERATED APPROVAL FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA), AND CONDITIONAL APPROVAL FROM EUROPEAN MEDICINES AGENCY (EMA), AS EARLY AS 2020.  Full Article

Genfit Cash As Of March 31 Amounted To 314.1 Million Euros
Tuesday, 30 Apr 2019 

April 30 (Reuters) - GENFIT SA ::REG-GENFIT: GENFIT: REPORTS FIRST QUARTER 2019 FINANCIAL INFORMATION.AS OF DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS TOTALED EUR 207.2 MILLION.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 314.1 MILLION COMPARED WITH EUR 255.2 MILLION ONE YEAR EARLIER.Q1 REVENUE EUR 1,000 VS EUR 37,000 YR AGO.  Full Article

Genfit Raises Circa $155.4 Million Gross In Nasdaq Offering
Thursday, 28 Mar 2019 

March 29 (Reuters) - GENFIT SA ::ANNOUNCED ON THURSDAY EXERCISE IN FULL OF THE OPTION GRANTED TO THE UNDERWRITERS OF ITS GLOBAL OFFERING AND NASDAQ GLOBAL SELECT MARKET LISTING TO PURCHASE UP TO 997,500 ADDITIONAL ADSS.GROSS PROCEEDS OF THE GLOBAL OFFERING INCREASED TO APPROXIMATELY $155.4 MILLION.TOTAL NUMBER OF GENFIT ORDINARY SHARES AND ADSS ISSUED IN THE GLOBAL OFFERING AMOUNTS TO 7 647 500 ORDINARY SHARES, INCLUDING 7 147 500 IN THE FORM OF ADSS.  Full Article

Genfit: Trading To Resume On March 27 At 1600 CET
Wednesday, 27 Mar 2019 

March 27 (Reuters) - GENFIT SA ::REG-GENFIT: GENFIT ANNOUNCES TRADING RESUMPTION OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS.REQUESTED THAT TRADING RESUMES AS FROM 4:00 P.M. CET, TODAY.  Full Article

Genfit: Trading Suspended In Context Of IPO On Nasdaq Global Select Market
Wednesday, 27 Mar 2019 

March 27 (Reuters) - GENFIT SA ::REG-GENFIT: GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS.TRADING OF ITS ORDINARY SHARES AND OF ITS OCEANES ON EURONEXT ACCESS HAS BEEN HALTED AT COMPANY'S REQUEST FROM 9:00 AM CET.SUSPENSION IN CONTEXT OF ITS INITIAL PUBLIC OFFERING ON NASDAQ GLOBAL SELECT MARKET.TRADING HALT WILL CONTINUE UNTIL A NEW COMMUNICATION IS RELEASED BY COMPANY..  Full Article

Genfit Announces Pricing Of Global Offering And Approval To List On Nasdaq Global Select Market
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Genfit SA ::GENFIT: GENFIT ANNOUNCES PRICING OF GLOBAL OFFERING AND APPROVAL TO LIST ON NASDAQ GLOBAL SELECT MARKET.GENFIT- GENFIT'S ADSS APPROVED FOR LISTING ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL "GNFT"; EXPECTED TO BEGIN TRADING ON MARCH 27.PRICING OF ITS GLOBAL OFFERING OF 6.15 MILLION NEW ORDINARY SHARES AT AN OFFERING PRICE OF $20.32 PER ADS.GENFIT - PRICING CONCURRENT PRIVATE PLACEMENT OF 500,000 ORDINARY SHARES IN EUROPE AND OTHER COUNTRIES OUTSIDE OF US AT PRICE OF EUR 18/SHARE.  Full Article

Genfit Announces Launch Of Proposed Global Offering And Nasdaq Listing
Thursday, 14 Mar 2019 

March 14 (Reuters) - Genfit SA ::REG-GENFIT ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING AND NASDAQ LISTING.ALL SECURITIES TO BE SOLD IN GLOBAL OFFERING WILL BE OFFERED BY GENFIT..GENFIT HAS APPLIED TO LIST ADSS TO BE SOLD IN U.S. OFFERING ON NASDAQ GLOBAL MARKET UNDER TICKER SYMBOL "GNFT".GENFIT INTENDS TO GRANT UNDERWRITERS FOR OFFERING A 30-DAY OPTION TO PURCHASE ADDITIONAL ADSS AND/OR ORDINARY SHARES IN AN AGGREGATE AMOUNT OF UP TO 15% OF TOTAL NUMBER OF ADSS AND ORDINARY SHARES PROPOSED TO BE SOLD IN GLOBAL OFFERING.CLOSINGS OF U.S. OFFERING AND EUROPEAN PRIVATE PLACEMENT WILL OCCUR SIMULTANEOUSLY,.COMPLETION OF GLOBAL OFFERING WOULD RESULT IN A DILUTION OF APPROXIMATELY 14% OF COMPANY'S OUTSTANDING SHARE CAPITAL ON A NON-DILUTED BASIS.TO USE APPROX EUR 13.3 MILLION TO PREPARE FOR POTENTIAL COMMERCIALIZATION OF ELAFIBRANOR FOR TREATMENT OF NASH BY BUILDING OUT ITS COMMERCIAL INFRASTRUCTURE.TO USE APPROXIMATELY EUR 5.3 MILLION ($6.0 MILLION) TO ADVANCE ITS RESEARCH PROGRAM ON USE OF ELAFIBRANOR.TO USE APPROXIMATELY EUR 5.3 MILLION ($6.0 MILLION) TO ADVANCE COMMERCIAL DEVELOPMENT OF AN IN VITRO DIAGNOSTIC ("IVD") TEST DESIGNED TO IDENTIFY NASH PATIENTS.TO USE APPROXIMATELY EUR 31.1 MILLION ($35.0 MILLION) TO CONDUCT AND COMPLETE ITS PLANNED GLOBAL PHASE 3 CLINICAL TRIAL OF ELAFIBRANOR FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS.  Full Article

Genfit S.A Files For U.S. IPO Of Up To $100 Million
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Genfit SA ::GENFIT S.A FILES FOR U.S. IPO OF UP TO $100 MILLION – SEC FILING.GENFIT S.A SAYS IT INTENDS TO APPLY TO HAVE ITS ADS LISTED ON NASDAQ GLOBAL MARKET UNDER THE SYMBOL "GNFT".GENFIT S.A SAYS SVB LEERINK, BARCLAYS, BRYAN, GARNIER & CO ARE AMONG UNDERWRITERS TO IPO.GENFIT S.A SAYS NATIXIS, ROTH CAPITAL PARTNERS, H.C. WAINWRIGHT & CO ARE AMONG UNDERWRITERS TO IPO.GENFIT S.A SAYS PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.  Full Article

Genfit And LabCorp Sign Licensing Agreement
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - GENFIT SA ::REG-GENFIT AND LABCORP SIGN A LICENSING AGREEMENT TO EXPAND ACCESS TO AN INNOVATIVE DIAGNOSTIC ASSAY FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH).AGREEMENT WILL EXPAND ACCESS TO INNOVATIVE NON-ALCOHOLIC STEATOHEPATITIS (NASH) LIVER DIAGNOSTIC TEST FOR THE CLINICAL RESEARCH MARKET.  Full Article

Genfit Announces Positive Phase 2 Results From Study Of Elafibranor In Primary Biliary Cholangitis
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE PHASE 2 RESULTS FROM STUDY OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS.SUBSTANTIAL REDUCTIONS IN ALKALINE PHOSPHATASE IN PATIENTS RECEIVING ELAFIBRANOR; 52% (80 MG) AND 44% (120 MG) WHEN COMPARED TO PLACEBO.ELAFIBRANOR SUCCESSFULLY MEETS PRIMARY ENDPOINT WITH HIGH STATISTICAL SIGNIFICANCE OF P<0.001.SIGNIFICANT RESPONSE RATE ON COMPOSITE ENDPOINT USED FOR REGULATORY APPROVAL, WITH 67% (80 MG) AND 79% (120 MG) RESPONDERS VERSUS 6.7% FOR PLACEBO (P15%, AND TOTAL BILIRUBIN (TB) Full Article

BRIEF-Genfit Presents Additional Data from Positive Phase 2 Clinical Trial Of Elafibranor

* SAID ON SATURDAY FURTHER ANALYSIS SHOWS SIGNIFICANT IMPROVEMENTS IN PBC CHOLESTATIC MARKERS AND REDUCTION ON IMMUNO/INFLAMMATION MARKERS